Utah Medical Products Reports Q2 Decline

Core Insights - Utah Medical Products reported a 4.3% decrease in GAAP revenue for Q2 2025, totaling $9.95 million, primarily due to a decline in sales to its largest customer, PendoTECH [1][2] - Diluted earnings per share (GAAP) were $0.94, with net income falling to $3.05 million, reflecting pressures on both gross and net margins [1][2] Financial Performance - Revenue decreased from $10.40 million in Q2 2024 to $9.95 million in Q2 2025, a drop of 4.3% [2] - Diluted EPS fell by 4.0% from $0.98 in Q2 2024 to $0.94 in Q2 2025 [2] - Gross profit margin contracted to 56.2%, down from 60.1% year-over-year, indicating a 3.9 percentage point decline [2][7] - Operating income decreased by 7.1% to $3.20 million, while net income fell by 11.7% [2] Sales and Market Dynamics - Domestic direct sales increased, with other device sales up 10% year-over-year, and Filshie Clip System sales in the U.S. rising by 8% [5] - However, domestic OEM sales dropped 38%, now representing only 12% of total domestic sales [5] - International sales declined by 11.6% in the first half of 2025 compared to the same period in 2024, with significant drops in Canada and Australia [6][11] Cost Management and Legal Exposure - The company reduced operating costs by $416,000 year-over-year, mainly through lower litigation expenses [8][12] - Legal costs remain a concern, with ongoing exposure related to product liability litigation [9][12] Strategic Focus and Future Outlook - Utah Medical Products focuses on product innovation, regulatory compliance, and international expansion, with a need to offset declining OEM sales [4] - Management anticipates an additional $200,000 reduction in PendoTECH-related revenue for the second half of 2025 compared to the same period in 2024 [14] - The company maintains a strong balance sheet with $82.2 million in cash and no debt, and has returned $1.0 million to shareholders through dividends [13]